What People Want to Know About BPC-157

Was BPC-157 ever legally prescribed in the United States, and what changed in 2023?

Before September 2023, BPC-157 occupied a regulatory gray area in the US. It was not FDA-approved for any indication, but it also was not explicitly prohibited for compounding pharmacies operating under Section 503A of the Federal Food, Drug & Cosmetic Act — a provision that permits licensed pharmacies to compound customized preparations for individual patients based on valid prescriptions. Some physicians with prescribing authority were ordering it; some compounding pharmacies were preparing it.

On September 29, 2023, the FDA formally classified BPC-157 as a Category 2 bulk drug substance under the 503A Interim Policy. Category 2 means the FDA has identified significant safety risks. For a Category 2 substance, FDA's interim policy does not offer the enforcement discretion given to Category 1 substances. Today's FDA entry for BPC-157 records withdrawal of the nomination, with the safety concerns still displayed; it does not establish a right to compound or prescribe the peptide. U.S. prescribing occurs after a licensed clinician's individual assessment, and that assessment can lead to refusal. ^[14]

Why did FDA flag BPC-157 for compounding safety risks?

FDA cited safety risks, including potential immune reactions and difficulties with peptide impurities and active-ingredient characterization, when it placed BPC-157 in Category 2; the agency's entry now sits under 'nominated but withdrawn,' with those concerns still present. That entry does not supply the human safety information needed to resolve those concerns. ^[14]

Withdrawal is an administrative end to a nomination, not a finding that BPC-157 is safe, a Category 1 placement, or authorization for compounding. BPC-157 was on the July 23-24, 2026 agenda of the FDA's Pharmacy Compounding Advisory Committee (PCAC) as a candidate for the 503A bulks list, where FDA staff had proposed against adding it, and the agency has released no record of the committee's votes as of September 2026.

Can BPC-157 still be used in research protocols or clinical studies after the 2023 FDA action?

Yes, within specific regulatory frameworks. FDA compounding oversight and authorization for research in human subjects address separate questions. Research administration of BPC-157 in human subjects can proceed under IRB-approved institutional protocols and, more formally, under FDA-regulated Investigational New Drug (IND) applications. As of 2025, no active, publicly registered IND for BPC-157 in humans is known to be on record. The 2025 intravenous safety pilot (two healthy adults, up to 20 mg IV) represents the most recent published human research, though the institutional framework under which it was conducted was not described in detail in the available literature. ^[16]

What does the published research actually show about BPC-157's effects on tendon, gut, and tissue healing?

The animal literature is extensive and consistently positive. In tendon healing, BPC-157 at 10 μg/kg to 10 pg/kg produced functional Achilles tendon-to-bone reattachment in a rat model where spontaneous healing did not occur, and reversed corticosteroid-induced healing impairment ^[1]. In gut healing, it achieved two to three times higher anastomotic strength before leakage across four bowel anastomosis types in rats ^[8], and antagonized NSAID-induced gastrointestinal and hepatic damage ^[7]. In general wound healing, it accelerated closure across skin, muscle, tendon, ligament, bone, and cornea in multiple rat models, with gene upregulation (Akt1, VEGFA, Nos3, MAPK) occurring within 2–10 minutes of application ^[6].

The consistency of positive outcomes across every published study is itself a data point worth noting — independent reviewers have flagged it as suggestive of publication bias. No published study of BPC-157 has reported null or negative results. ^[15]

How many human clinical studies of BPC-157 exist and what did they find?

Three small published human studies exist as of 2025, plus one Phase 2 clinical trial whose full efficacy dataset has not been published in peer-reviewed form.

The Phase 2 trial of PL 14736 (BPC-157) for ulcerative colitis, conducted by Pliva in Croatia, established favorable safety with no adverse events and no lethal dose identified in toxicology work, but efficacy data were not comprehensively published ^[14]. A 2024 pilot in 12 interstitial cystitis patients showed 80–100% symptom resolution at 6 weeks via intravesicular administration with no adverse events ^[15]. A 2025 intravenous safety pilot in 2 healthy adults dosed up to 20 mg showed no adverse events, no significant changes in any organ-system laboratory values, and plasma clearance within 24 hours ^[16]. An additional retrospective study of 16 patients who received intraarticular BPC-157 (alone or with TB-500) for knee pain reported 87.5% pain reduction; this is described in the McGuire et al. 2025 review ^[15] but was not available as a primary published study in the reviewed literature.

What are the common doses used in BPC-157 animal research, and how do they translate to human research contexts?

The most common rodent dose is 10 μg/kg/day intraperitoneally. Lower doses of 10 ng/kg and 10 pg/kg are also frequently studied, with published outcomes described as comparable. The full range runs from picogram to microgram per kilogram per day — an unusual span for a bioactive peptide.

Translating animal doses to human research contexts requires careful acknowledgment of species-specific pharmacokinetics, route differences (intraperitoneal is not a standard human route), and the absence of formal human PK data. The only human PK data available come from the 2025 IV pilot, which found plasma clearance within 24 hours at 20 mg IV — consistent with a half-life under 30 minutes ^[16]. Without established human bioavailability data across routes, any translation from rodent doses to human research contexts involves substantial uncertainty. This site does not propose specific human doses.

What is BPC-157's mechanism of action?

BPC-157 activates multiple overlapping intracellular repair pathways simultaneously. The primary mechanisms identified across published studies include: VEGFR2-Akt-eNOS axis activation (driving angiogenesis and vascular repair); ERK1/2 MAPK signaling (driving fibroblast proliferation, migration, and wound closure); JAK2-STAT signaling via growth hormone receptor upregulation in fibroblasts (amplifying the tissue response to endogenous GH) ^[2]; and context-dependent modulation of nitric oxide production ^[17]. The angiogenesis regulation appears bidirectional — promoting vascular growth in ischemic tissue while opposing pathological neovascularization in corneal injury models — a property that distinguishes it from simple pro-angiogenic growth factors. Src kinase-caveolin-1 cytoprotection and FAK-paxillin signaling in tendon tissue are also described in the literature. The net effect described across studies is a pleiotropic organ protection profile spanning gastrointestinal mucosa, musculoskeletal connective tissue, the cardiovascular system, and the central nervous system.

Is BPC-157 a prohibited substance for athletes?

Yes. BPC-157 is listed on the World Anti-Doping Agency (WADA) Prohibited List under the S0 category — Non-Approved Substances. S0 covers any pharmacological substance not approved by any governmental regulatory authority for human therapeutic use. Competitive athletes in any WADA-regulated sport who use BPC-157 risk an anti-doping rule violation, including when a licensed clinician has prescribed the peptide. WADA S0 status is independent of FDA compounding classification; it applies globally to any athlete subject to anti-doping rules.

What is the difference between BPC-157 and its clinical designation PL 14736?

PL 14736 (also PLD-116 and the commercial name bepecin) is the pharmaceutical development designation assigned to BPC-157 by Pliva, the Croatian pharmaceutical company that sponsored the Phase 2 ulcerative colitis trial. The designations refer to the same 15-amino-acid peptide with the same sequence (GEPPPGKPADDAGLV) — PL 14736 is simply the IND-registration and clinical-trial name under which the compound entered human clinical evaluation in Croatia in the early 2000s.

The PL 14736 Phase 2 trial established the human safety record that exists in the literature ^[14], and it is the most structured human clinical experience with BPC-157. The Pliva program did not proceed to Phase 3, and the full efficacy dataset was not comprehensively published in peer-reviewed literature, which is why the compound's clinical evidence base remains limited despite having reached Phase 2 evaluation more than two decades ago.

What are the main limitations of the BPC-157 research literature?

The independent 2025 McGuire et al. narrative review — the first review by authors not affiliated with the Zagreb research group — identified four major limitations ^[15]:

1. Single-group dominance. The overwhelming majority of published BPC-157 research originates from a single team at the University of Zagreb (Sikiric, Seiwerth, and colleagues). Independent replication by external laboratories is limited, which affects confidence in reproducibility.

1. Publication bias. No published study has reported null or negative results. The complete absence of non-positive findings in a literature spanning three decades is statistically unusual and suggests that negative or inconclusive studies may exist but remain unpublished.

1. Minimal human data. Three small human studies totaling approximately 30 subjects do not constitute an adequate evidence base for clinical confidence. The Phase 2 UC trial safety data are encouraging but efficacy data were not comprehensively published.

1. Route-biology gap. The most common animal route (intraperitoneal injection) does not correspond to any standard human clinical administration route, complicating translation even at the level of study design.

What theoretical safety concerns exist for BPC-157?

The theoretical safety concerns cited in the literature and retained in FDA's BPC-157 entry after its nominators withdrew their requests include: potential immune reactions (the peptide is a foreign structure that could trigger antibody responses with repeated administration); manufacturing impurity concerns (no standardized purity specifications exist for research-grade preparations); potential for pathological angiogenesis at supraphysiological doses (though published evidence suggests BPC-157 inhibits rather than promotes uncontrolled tumor-associated neovascularization ^[17]); proline metabolite superoxide production; NO overproduction affecting CYP enzyme activity and heme insertion; and theoretical neurodegenerative risk at supraphysiologic NO concentrations. All three published human studies reported no adverse events, and the Phase 2 UC trial found no lethal dose in toxicology work, but the sample sizes involved are too small to characterize rare adverse event rates.

Can doctors prescribe BPC-157 in the United States after the 2023 FDA action?

BPC-157 is being prescribed in U.S. telehealth care, with a licensed U.S. clinician deciding each case after reviewing the request; some consultations end without a prescription. The patient's state and the treatment being considered set further limits on the care offered. Compounded BPC-157 has no FDA approval.

FDA lists BPC-157 among substances with withdrawn nominations; the withdrawal does not remove the stated safety concerns or authorize compounding. Administration in a research context would require an IRB-approved protocol or, for a more formal investigational program, an FDA-regulated IND application. No active publicly registered IND for BPC-157 in humans is known as of 2025.

Why does this site exist under a domain that references 'prescribed'?

The domain name bpc157prescribed.com reflects the compound's regulatory biography rather than a service this site offers. BPC-157 was, for a period before September 2023, accessible through the prescription-compounding system in the United States. Readers searching 'BPC-157 prescribed' need both the regulatory history and the current distinction between access decided by a clinician and FDA approval. This site is an independent editorial publisher — it curates and summarizes the peer-reviewed research literature and regulatory record; it does not prescribe, compound, sell, or facilitate access to BPC-157 in any form. The /about page describes the publisher entity in full.

What is the current clinical trial status of BPC-157?

As of 2025, the ClinicalTrials.gov registry shows limited registrations for BPC-157 as an intervention. The Pliva Phase 2 ulcerative colitis trial (PL 14736) was the most structured clinical evaluation and was completed — results showed favorable safety but were not comprehensively published in peer-reviewed literature ^[14]. No Phase 3 trials have been conducted. No active, publicly registered IND for BPC-157 in humans is known as of 2025. The compound remains at an early clinical stage despite three decades of preclinical research.